Should I buy or sell MaxCyte stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MXCT shares. View MXCT analyst ratings or view top-rated stocks .

What is MaxCyte's stock price target for 2024?

3 brokerages have issued 12 month price objectives for MaxCyte's shares. Their MXCT share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price. View analysts price targets for MXCT or view top-rated stocks among Wall Street analysts .

How have MXCT shares performed in 2023?

MaxCyte's stock was trading at $5.46 at the beginning of 2023. Since then, MXCT shares have decreased by 13.0% and is now trading at $4.75. View the best growth stocks for 2023 here .

When is MaxCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our MXCT earnings forecast .

How were MaxCyte's earnings last quarter?

MaxCyte, Inc. (NASDAQ:MXCT) issued its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The company had revenue of $8.01 million for the quarter, compared to the consensus estimate of $7.90 million. MaxCyte had a negative net margin of 98.44% and a negative trailing twelve-month return on equity of 15.35%.

What guidance has MaxCyte issued on next quarter's earnings?

MaxCyte issued an update on its third quarter 2023 earnings guidance on Wednesday, October, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.80 million-$8.00 million, compared to the consensus revenue estimate of $11.35 million.

When did MaxCyte IPO?

(MXCT) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.

Who are MaxCyte's major shareholders?

MaxCyte's stock is owned by a number of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (3.63%), Massachusetts Financial Services Co. MA (1.89%), American Century Companies Inc. (1.65%), River & Mercantile Asset Management LLP (1.42%), Ameriprise Financial Inc. (1.26%) and Northern Trust Corp (0.77%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Richard Douglas and Thomas M Ross. View institutional ownership trends .

How do I buy shares of MaxCyte?

Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

MaxCyte Stock Price, News & Analysis (NASDAQ:MXCT)

$4.80

+0.05 (+1.05%)

(As of 10:33 AM ET)

Compare

Today's Range: $4.64
▼
$4.80
50-Day Range: $2.60
▼
$4.87
52-Week Range: $2.45
▼
$6.11

Volume: 108,986 shs
Average Volume: 591,131 shs
Market Capitalization: $497.18 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.50

MaxCyte MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 100.0% Upside
$9.50 Price Target
Short Interest: Healthy
3.25% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.62
Based on 4 Articles This Week
Insider Trading: Selling Shares
$60,050 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.43) to ($0.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

Medical Sector

273rd out of 948 stocks

Commercial Physical Research Industry

7th out of 13 stocks

3.5

Analyst's Opinion

Consensus Rating
MaxCyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.50, MaxCyte has a forecasted upside of 100.0% from its current price of $4.75.
Amount of Analyst Coverage
MaxCyte has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
3.25% of the float of MaxCyte has been sold short.
Short Interest Ratio / Days to Cover
MaxCyte has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in MaxCyte has recently decreased by 8.90%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
MaxCyte does not currently pay a dividend.
Dividend Growth
MaxCyte does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MXCT.

3.1

News and Social Media Coverage

News Sentiment
MaxCyte has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for MaxCyte this week, compared to 1 article on an average week.
Search Interest
2 people have searched for MXCT on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added MaxCyte to their MarketBeat watchlist in the last 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MaxCyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,050.00 in company stock.
Percentage Held by Insiders
Only 6.00% of the stock of MaxCyte is held by insiders.
Percentage Held by Institutions
62.25% of the stock of MaxCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for MaxCyte are expected to decrease in the coming year, from ($0.43) to ($0.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MaxCyte is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MaxCyte is -12.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MaxCyte has a P/B Ratio of 2.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About MaxCyte Stock (NASDAQ:MXCT)

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

MXCT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MXCT Stock News Headlines

December 1, 2023 | americanbankingnews.com

Craig Hallum Initiates Coverage on MaxCyte (NASDAQ:MXCT)

November 9, 2023 | finanznachrichten.de

MaxCyte, Inc.: MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance

December 1, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

November 8, 2023 | morningstar.com

MaxCyte Inc MXCT

October 5, 2023 | bizjournals.com

MaxCyte shares plunge after Rockville biotech firm sharply lowers 2023 revenue outook

October 5, 2023 | markets.businessinsider.com

Cell Engineering MaxCyte Faces Challenge, Analysts Express Concerns Over Near-Term Prospects Amid Revenue Decline

October 5, 2023 | finanznachrichten.de

MaxCyte, Inc: MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance

October 5, 2023 | benzinga.com

MaxCyte, Rivian Automotive And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

December 1, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

October 5, 2023 | finance.yahoo.com

The past year for MaxCyte (LON:MXCT) investors has not been profitable

October 5, 2023 | investorplace.com

Why Is MaxCyte (MXCT) Stock Down 21% Today?

October 4, 2023 | marketwatch.com

MaxCyte Shares Sink 21% Amid Lower-Than-Expected FY Revenue Views

September 6, 2023 | finanznachrichten.de

MaxCyte, Inc: MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

September 6, 2023 | finance.yahoo.com

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

September 5, 2023 | finance.yahoo.com

MaxCyte to Participate in Baird Global Healthcare Conference

August 11, 2023 | finanznachrichten.de

MaxCyte, Inc.: MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

July 10, 2023 | finanznachrichten.de

MaxCyte, Inc: MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

July 8, 2023 | finance.yahoo.com

MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 77% of the company

June 9, 2023 | seekingalpha.com

PRTS, CRBU and NDLS are among after hour movers

May 30, 2023 | msn.com

MaxCyte: Engineering The Next Biotech Wave

May 18, 2023 | finanznachrichten.de

MaxCyte, Inc: MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

May 12, 2023 | msn.com

Recap: MaxCyte Q1 Earnings

May 11, 2023 | seekingalpha.com

MaxCyte, Inc. 2023 Q1 - Results - Earnings Call Presentation

May 10, 2023 | finance.yahoo.com

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates

May 10, 2023 | finance.yahoo.com

MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

May 4, 2023 | finance.yahoo.com

MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

April 12, 2023 | finance.yahoo.com

MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023

See More Headlines

Receive MXCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MaxCyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/01/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Commercial physical research
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MXCT
CUSIP: N/A
CIK: 1287098
Web: maxcyte.com
Phone: 301-944-1700
Fax: 301-944-1703
Employees: 125
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $9.50
High Stock Price Target: $12.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +100.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.37)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,570,000.00
Net Margins: -98.44%
Pretax Margin: -98.44%
Return on Equity: -15.35%
Return on Assets: -13.55%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.87
Quick Ratio: 12.12

Sales & Book Value

Annual Sales: $38.05 million
Price / Sales: 12.93
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.25 per share
Price / Book: 2.11

Miscellaneous

Outstanding Shares: 103,576,000
Free Float: 97,361,000
Market Cap: $491.99 million
Optionable: Optionable
Beta: 0.84

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Douglas Arthur Doerfler (Age 67)
Founder, President, CEO & Executive Director
Comp: $1.2M
Dr. Cenk Sumen Ph.D. (Age 49)
Chief Scientific Officer
Comp: $575.6k
Mr. Maher Masoud (Age 48)
Executive VP, General Counsel & Secretary
Comp: $612.07k
Mr. Douglas J. Swirsky CFA (Age 54)
CPA, Chief Financial Officer
Mr. Ronald Evan Holtz CPA (Age 65)
Ph.D., Executive Vice President of Administration
Comp: $649.38k
Mr. Sean Menarguez
Director of Investor Relations
Mr. Thomas Michael Ross (Age 62)
Executive Vice President of Global Sales & Marketing
Mr. Jack Horgan
Vice President of Corporate Development
Dr. J. Stark Thompson Ph.D. (Age 81)
Consultant
Comp: $84.71k
Dr. James Brady Ph.D.
Senior VP of Technical Applications & Customer Support

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MXCT Stock Analysis - Frequently Asked Questions

Should I buy or sell MaxCyte stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MaxCyte in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MXCT shares.
View MXCT analyst ratings or view top-rated stocks.
What is MaxCyte's stock price target for 2024?: 3 brokerages have issued 12 month price objectives for MaxCyte's shares. Their MXCT share price targets range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 100.0% from the stock's current price.
View analysts price targets for MXCT or view top-rated stocks among Wall Street analysts.
How have MXCT shares performed in 2023?: MaxCyte's stock was trading at $5.46 at the beginning of 2023. Since then, MXCT shares have decreased by 13.0% and is now trading at $4.75.
View the best growth stocks for 2023 here.
When is MaxCyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our MXCT earnings forecast.
How were MaxCyte's earnings last quarter?: MaxCyte, Inc. (NASDAQ:MXCT) issued its quarterly earnings results on Wednesday, November, 8th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01. The company had revenue of $8.01 million for the quarter, compared to the consensus estimate of $7.90 million. MaxCyte had a negative net margin of 98.44% and a negative trailing twelve-month return on equity of 15.35%.

What guidance has MaxCyte issued on next quarter's earnings?: MaxCyte issued an update on its third quarter 2023 earnings guidance on Wednesday, October, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $7.80 million-$8.00 million, compared to the consensus revenue estimate of $11.35 million.
When did MaxCyte IPO?: (MXCT) raised $150 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 12,000,000 shares at $11.50-$13.50 per share.
Who are MaxCyte's major shareholders?: MaxCyte's stock is owned by a number of institutional and retail investors. Top institutional investors include Stonepine Capital Management LLC (3.63%), Massachusetts Financial Services Co. MA (1.89%), American Century Companies Inc. (1.65%), River & Mercantile Asset Management LLP (1.42%), Ameriprise Financial Inc. (1.26%) and Northern Trust Corp (0.77%). Insiders that own company stock include Casdin Partners Master Fund, L, Douglas Doerfler, John Joseph Johnston, Richard Douglas and Thomas M Ross.
View institutional ownership trends.
How do I buy shares of MaxCyte?: Shares of MXCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MXCT) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial